Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174621
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Marín Jiménez, Ignacio | - |
dc.contributor.author | Zabana, Yamile | - |
dc.contributor.author | Rodríguez Lago, Iago | - |
dc.contributor.author | Marín, Laura | - |
dc.contributor.author | Barreiro de Acosta, Manuel | - |
dc.contributor.author | Esteve i Comas, Maria | - |
dc.date.accessioned | 2021-03-04T14:29:28Z | - |
dc.date.available | 2021-03-04T14:29:28Z | - |
dc.date.issued | 2020-05-15 | - |
dc.identifier.issn | 0210-5705 | - |
dc.identifier.uri | http://hdl.handle.net/2445/174621 | - |
dc.description.abstract | COVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was described in China in late 2019. There are currently more than three million diagnosed cases, constituting a pandemic which has caused a worldwide crisis. The devastating effects of this infection are due to its highly contagious nature and although mild forms predominate, in absolute values, the rates for severe forms and mortality are very high. The information on the characteristics of the infection in inflammatory bowel disease is of special interest, as these patients have higher attendance at health centres, which may increase their risk of infection. Furthermore, the treatments used to control the inflammatory activity may modify the disease course of COVID-19. The Spanish Working Group on Crohn's Disease and Ulcerative Colitis and the Spanish Nurses Working Group on Inflammatory Bowel Disease have prepared this document as a practical response to some common questions about the treatment of these patients. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | spa | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.gastrohep.2020.05.003 | - |
dc.relation.ispartof | Gastroenterologia y Hepatologia, 2020, vol. 43(7), num. 7, p. 408-413 | - |
dc.relation.uri | https://doi.org/10.1016/j.gastrohep.2020.05.003 | - |
dc.rights | cc-by-nc-nd (c) Marín Jiménez et. al., , 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Colitis ulcerosa | - |
dc.subject.classification | Malaltia de Crohn | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Ulcerative colitis | - |
dc.subject.other | Crohn's disease | - |
dc.title | COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020) | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 704321 | - |
dc.date.updated | 2021-03-04T14:29:28Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
704321.pdf | 501.64 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License